Cart
×
Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA
BioMarin Update for the Duchenne Community: 01 June 2016
We are sharing the following update from BioMarin. We would like to update the patient community in light of the recent announcement regarding the EMA marketing application. BioMarin is […]
Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy
Going Backwards to Go Forwards
I imagine that by now you have heard the news that BioMarin has withdrawn its Kyndrisa™ (drisapersen) Marketing Authorization Application (MAA) in Europe. Like you, I am heartbroken and […]
BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa™ (drisapersen) in Europe
CUREDUCHENNE CARES EXPANDS PHYSICAL THERAPY TRAINING SESSIONS
Celeste Graham, PT, and Doug Levine, PT, join Jennifer Wallace, PT and Director of the CureDuchenne Cares program, who initially developed the workshops and training sessions. Together these physical therapists […]
The Wait for An Approved Drug for Duchenne Continues
The wait continues. Sarepta Therapeutics announced this morning that the FDA will not complete the review of the eteplirsen new drug application by the PDUFA date. Considering the thousands […]